The challenges to effective drug delivery to brain tumors are twofold: (1) there is a lack of non-invasive methods of local delivery and (2) the blood-brain barrier limits systemic delivery. Intranasal delivery of therapeutics to the brain overcomes both challenges. In mouse model of malignant glioma, we observed that a small fraction of intranasally delivered neural stem cells (NSCs) can migrate to the brain tumor site. Here, we demonstrate that hypoxic preconditioning or overexpression of CXCR4 significantly enhances the tumor-targeting ability of NSCs, but without altering their phenotype only in genetically modified NSCs. Modified NSCs deliver oncolytic virus to glioma more efficiently and extend survival of experimental animals in the context of radiotherapy. Our findings indicate that intranasal delivery of stem cell-based therapeutics could be optimized for future clinical applications, and allow for safe and repeated administration of biological therapies to brain tumors and other CNS disorders.
INTRODUCTION
Malignant gliomas (MGs), a group of high-grade primary adult brain tumors, are classically known for being highly aggressive and incurable. With an average median survival of only 14.6 months following the current standard-of-care treatment regimen, MGs are in desperate need of novel and effective treatment strategy (Stupp et al., 2005) . The bloodbrain barrier (BBB) renders several highly effective systemic chemotherapeutic agents ineffective in the setting of MGs (Lesniak and Brem, 2004; Lesniak et al., 2001) . Along with presence of the BBB there are several other intrinsic tumor characteristics that orchestrate the eventual failure of the current standard of care, such as inherent resistance of tumor cells to chemotherapeutic agents (Decleves et al., 2006; Tian et al., 2015) , complex interplay between radiation and hypoxia that results in radioresistance (Dahan et al., 2014; Moeller et al., 2004; Vordermark et al., 2004) , and the fluid phenotype of cancer cells that seamlessly transition between differentiated and dedifferentiated forms following chemotherapy (Auffinger et al., 2014; Safa et al., 2015) .
The particular anatomy of the olfactory and trigeminal neural pathways connects the nasal mucosa directly with the brain and the perivascular pathway by circumventing the BBB (Jiang et al., 2015) . Using intranasal delivery, several therapeutic agents, such as small molecules, proteins, hormones, and nanoparticles, have been shown to successfully reach the brain (Andrade, 2015; Elnaggar et al., 2015; Feng et al., 2012; Kim et al., 2012) . The intranasal route has also been explored for delivering larger cell-based carriers such as mesenchymal stem cells (MSCs) in the setting of ischemic brain injury and Parkinson's disease (Danielyan et al., 2011; van Velthoven et al., 2010) . Reitz et al. (2012) demonstrated that intranasally delivered neural stem cells (NSCs) localize to the intracranial human or murine glioma xenografts in mouse models. Furthermore, our group has shown that therapeutic MSCs and NSCs when delivered to the nasal cavity not only travel to intracranial tumors in mice, but also prolong the animals' survival Gutova et al., 2015) . Further validation of intranasal delivery of various therapeutics to the brain is of particular interest in the context of MG.
One of the emerging front-runners of experimental therapeutic options for targeting MG is virotherapy whereby oncolytic viruses (OVs), such as CRAd-S-pK7 (Ulasov et al., 2007) , selectively infect tumor cells and induce a specific anti-glioma cytotoxic response. We have shown that stem cells not only can efficiently deliver OVs to experimental glioma (Ahmed et al., 2011b (Ahmed et al., , 2013 Morshed et al., 2015) , but also delay the premature viral neutralization by the host's immune system (Ahmed et al., 2010) . Intranasal delivery of OVs loaded in stem cell carriers allows for a non-invasive and repeatable treatment regimen, although to date the feasibility of such an approach has not investigated.
As MGs are known for the presence of prominent intratumoral areas of hypoxia Keunen et al., 2011; Pistollato et al., 2010; Womeldorff et al., 2014) , hypoxia-driven glioma-tropic NSCs (Zhao et al., 2008) can provide an optimal cell-based carrier for OV delivery. We had previously demonstrated that hypoxia can enhance the motility of NSCs, and CXCR4 overexpression is the main mechanism contributing to this phenomenon. The expression of SDF-1, a CXCR4 ligand, is significantly associated with the hypoxic environment of MG (Zhao et al., 2008) . We and others have also previously shown that SDF-1 expression is significantly higher in glioma tissue after radiation therapy Zhao et al., 2008) . Therefore, in this study we investigated whether CXCR4 overexpression on the surface of NSCs either by hypoxic preconditioning or genetic modification of NSCs allows for enhanced migratory properties, and the therapeutic outcome of intranasal delivery of OV-loaded CXCR4-expressing NSCs in glioma-bearing mice.
We hypothesized that intranasal delivery of CXCR4-expressing NSCs loaded with CRAd-S-pK7 will lead to tumor-specific delivery of OV and increased survival in the mouse model of glioma. Our results show that CXCR4-enhanced NSCs possess higher motility toward SDF-1 gradient in vitro, delivered OV to glioma xenograft more efficiently and provided a survival advantage to irradiated mice bearing aggressive intracranial tumors. Moreover, genetically modified NSCs would also retain their stemness and genetic stability, making them a desirable cell carrier for the intranasal delivery of therapeutics to the MG. These studies establish an effective strategy to significantly improve stem cell-based oncolytic virotherapy via selective enhancement of tumor tropism signaling. Further refinement and expansion strategies beyond the CXCR4/SDF-1 signaling axis should also be explored to optimize the clinical translation value of this approach.
RESULTS

Hypoxic Preconditioning Enhances the Tropism of NSCs toward Glioma
The natural tumor tropism of stem cells is the foundation for using NSCs as a therapeutic conduit to accomplish targeted delivery of therapeutics (Ahmed et al., 2011a (Ahmed et al., , 2013 Balyasnikova et al., 2014) . The hypoxic environment of glioma is thought to contribute to the mechanism of NSC tropism (Zhao et al., 2008) .
The migratory preference of NSCs toward glioma cell lines were explored and defined for both N 
Gradient In Vitro
We previously demonstrated that brain radiation therapy (XRT) increases the expression of SDF-1 in U87MG xenograft tumor , suggesting that the CXCR4/SDF-1 signaling axis could potentially be utilized to optimize tumor tropism of NSCs toward irradiated glioma tissue. Here we show that hypoxia-treated NSCs show about a 2-fold increase in the surface expression of CXCR4 in H NSCs over N NSCs (Figure 2A ; n = 3, *p < 0.0001) as determined by flow cytometry. Although CXCR7, another receptor interacting with SDF-1, shows hypoxia-induced surface expression in NSCs, the increase in protein expression in H NSCs was <10% when compared with N NSC controls ( Figure S1C ). Genetic modification of NSCs via transduction with lentivirus encoding for CXCR4, significantly increased mRNA CXCR4 expression in CXCR4 NSCs in comparison with cells transduced with control lentivirus VC NSCs (n = 3, *p < 0.0001), as determined by qRT-PCR ( Figure 2B ). Nearly all transduced NSCs were expressing CXCR4 on the cell surface as shown by flow cytometry ( Figure 2C ), which is about 4 and 2.5 times higher than in N NSCs and H NSCs, respectively. These results demonstrate that CXCR4 is a potential receptor responsible for increased migration of NSCs toward glioma tumors secreting SDF-1. The higher CXCR4 expression in H NSCs and CXCR4 NSCs correlated with the increase in chemotaxis toward SDF-1 gradient in 3D migration assays ( Figure 3A) . Specifically, H NSCs demonstrated a significantly increased migration distance in response to SDF-1 stimulation (10 ng) upon 24 hr of hypoxia treatment (79 ± 19 pixels; n = 30 cells) compared with N NSCs (23 ± 2 pixels; n = 30; *p < 0.001).
Moreover, CXCR4 NSCs showed significantly improved migration over H NSCs within 24 hr toward the SDF-1-containing reservoir (114 ± 28 pixels; n = 30, *p < 0.001). The presence of blocking antibody against CXCR4 immunoglobulin G, however, abolished the migration toward the SDF-1 source for both H NSCs and CXCR4 NSCs ( Figure 3B ), suggesting a key dependence on CXCR4 in SDF-1-induced NSC migration. Hypoxia induces a phenotypic shift toward neural progenitors in NSCs, whereas genetic modification of NSCs to overexpress CXCR4 does not change their phenotype.
To ensure that 1% hypoxic culture for 24 hr does not negatively affect the therapeutic potentials of NSCs, we conducted an analysis of mRNA and protein expression for markers of stemness and differentiation by qRT-PCR, western blotting, and immunocytochemistry (ICC). The mRNA expression for SOX2, hNESTIN, MUSASHI (markers of neural stemness), bIII-TUBULIN, and GFAP (markers of differentiation) were assessed by qRT-PCR ( Figure 4A ). Our results demonstrate significant changes in stemness markers after 24 hr of treatment with hypoxia, where hNESTIN mRNA levels H NSCs effectively cross the culture insert membrane and accumulate within tumorspheres of patientderived GBM43 glioma cells visualized with DAPI nuclear stain (blue) (A) and U87MG mCherry cells (B). Right panels represent quantification of the relative presence of GFP + NSCs, indicating significantly higher numbers of GFP + H NSCs than N NSCs inside the tumorspheres by 24 hr of co-culture (n = 5, Student's t test; ***p < 0.001 for GBM43, *p < 0.05 U87MG). Scale bars, 100 mm. (C) Collagen hydrogel migration assay further demonstrates the enhanced tumor tropism by NSCs after hypoxia pretreatment; Confocal z-stack 3D reconstruction shows GFP + NSCs (green) seeded on top of the collagen hydrogel layer migrating to the bottom of the culture dishes in both GBM43blue (blue cells, top panels) and U87MG mCherry adherent cultures (red cells, bottom panel) by 12 hr. Quantification of migrated GFP + NSCs by microscopy visual field (right) confirms the increased ''homing'' by H NSCs in both the GBM43blue and U87MG mCherry cells after hypoxia pretreatment (n = 7; **p < 0.01, Student's t test, error bars with SEM).
significantly increased (443 ± 36-fold increase over normoxia; n = 3, ***p < 0.001), whereas SOX2 and MUSASHI were significantly decreased (0.04 ± 0.04-and 0.33 ± 0.11-fold respectively; n = 3, ***p < 0.001) in comparison with normoxia, indicating a possible phenotypic shift toward the more motile neural progenitor stages of NSCs. Moreover, the neural differentiation marker bIII-TUBULIN was significantly reduced (0.45 ± 0.10-fold; n = 3, ***p < 0.001) in comparison with normoxia. Worth noting is that the astroglial marker GFAP (data not shown) mRNA was undetectable under either normoxia or hypoxia treatments. ICC staining for the definitive astroglial differentiation marker S100B showed complete absence in NSCs under either condition, confirming that hypoxic preconditioning did not induce NSC differentiation toward astrocytes ( Figure S2C ). ICC for stemness and differentiation marker expressions supports the qRT-PCR results ( Figures S2A-S2C ). These observations confirm that, while hypoxic preconditioning allows NSCs to largely maintain their stem cell profiles, a phenotypic shift toward hNESTIN + neural progenitor stages with reduced terminal differentiation potentials is the predominant outcome for 24-hr hypoxia exposure, in agreement with the observed increase in motility and tumor tropism. Consistent with knowledge that hypoxia induces upregulation of HIF1a, we observed the increase in HIF1a expression in hypoxia-treated NSCs, which was accompanied by activation of signaling as judged by an increase in pAKT ( Figures S2D-S2F ). Similar induction of pAKT was accomplished by treatment of NSCs with SDF-1. Both SDF-1 and hypoxia-induced pAKT were partially blocked by the CXCR4 receptor antagonist AMD3100, thus indicating a CXCR4-dependent mechanism of activation of downstream signaling in hypoxia-treated cells. Hypoxia-induced signaling within the NSCs can involve complex signaling networks that are known to regulate the apoptosis, differentiation, and migratory/metastatic behaviors of many normal or cancerous cell types (Barriga et al., 2013; Guan et al., 2015; Guo et al., 2014; Speth et al., 2014) . In addition, activation of HIF1a signaling in NSCs can trigger biological events not consistent with their intended use as therapeutic carriers. Therefore, given the established CXCR4/SDF-1 axis in tropism of NSCs toward glioma, it is of high interest to examine whether modification of NSCs via ectopic overexpression of CXCR4 results in phenotypic stability of NSCs. The analysis of markers of stemness and differentiation at mRNA and protein levels in CXCR4 NSCs confirmed that overexpression of CXCR4 minimally affected the expression profiles of hNESTIN, SOX2, and bIII TUBULIN in CXCR4 NSCs. Importantly, cytogenetic analysis revealed that CXCR4 NSCs cells retain their normal karyotype after genetic modification via lentiviral transduction ( Figure 4D ).
XRT Increases SDF-1 Expression in GBM43 Glioma Xenografts
To confirm the potential significance of SDF-1 in contributing to migration of NSCs in vivo, we euthanized control and XRT-treated mice and compared brain tissues for SDF-1 expression. The analysis of H&E staining and ICC of brain tissue sections from control and irradiated mice demonstrates reduced tumor burden after XRT, and significantly increased SDF-1 levels at the tumor sites after XRT treatment ( Figure 5A ; n = 22 sections from 3 animals/group, ***p < 0.001). Quantitative analysis for positive immunostaining demonstrated a nearly 4-fold increase in XRT-treated mice versus control animals ( Figure 5B ). These findings are in agreement with our previous observation of an increase in SDF-1 expression in irradiated U87MG xenografts and highlight the significance of utilizing the SDF-1/CXCR4 axis to advance NCSs as therapeutic carriers to glioblastoma in conjunction with XRT treatment .
Hypoxia-Treated NSCs Support the Loading and Replication of CRAd-S-pK7
Propagation of OVs in NSCs (HB1.F3.CD cells) utilized in this study have been extensively characterized by our group (Ahmed et al., 2011a (Ahmed et al., , 2011b (Ahmed et al., , 2013 (Figure S4A) . Following the standardized treatment protocol, we established that a fractionated dose of XRT significantly improves survival of mice with both GBM43 (extension of 9 days of median survival over PBS only with XRT; n = 8 animals/group, *p < 0.05, log-rank test) and GBM6 (extension of 8 days of median survival over PBS only with XRT; n = 5, *p < 0.05) intracranial xenografts ( Figure 6A Figure S4B ). These data confirm our hypothesis that hypoxic preconditioning of intranasally delivered NSCs not only enhances tumor tropism and OV delivery but also results in therapeutic benefits in aggressive PDX models of GBMs. tissue sections (n = 10 from 3 animals/group, ***p < 0.001). Furthermore, staining of tissue sections for hexon after CXCR4 NSC-OV therapy also confirmed that the ability of CXCR4 NSC to deliver OVs to the tumor burden is substantially improved in comparison with OV therapy delivered by control VC NSCs ( Figure 7B ).
DISCUSSION
In this study we explored the strategy of enhancing the migratory phenotype of NSCs for intranasal delivery of therapeutic cell carriers for the treatment of MG. This approach is thought to overcome several hurdles that stand in the way of an effective glioma-targeting treatment regimen. We delivered multiple doses of hypoxia-preconditioned NSCs loaded with OVs directly to the nasal cavity of mice bearing intracranial tumors. Mice treated with this modality had significant survival advantage over other control groups. Furthermore, selective genetic enhancement in NSC surface expression of CXCR4 receptor mimics the beneficial impact of hypoxia on NSC migration without the hypoxia-associated phenotypic changes in NSCs. Thus, stable genetic manipulation of NSCs can selectively augment their therapeutic functions against GBM, while maintaining intracellular OV replication. Intranasal delivery effectively addresses the issue of circumventing the BBB and allows for non-invasive repeated dosing. Although this modality has been successfully utilized for delivering a variety of growth factors, hormones, and neuropeptides (Chapman et al., 2013) to the CNS, the efficacy of this route to deliver cell-based carriers is still in its early phase of exploration. As the tropism of NSCs to intracranial glioma and other malignancies is well validated (Aboody et al., 2000; Gutova et al., 2015; Kanojia et al., 2015) , the intranasal delivery imposes strict requirements for fast migration of therapeutic cell carriers from the nasal cavity to prevent rapid clearance from the nasal cavity. In this respect, MSCs genetically modified to overexpress CXCR4 have been shown to possess higher migratory properties and therapeutic potential in an acute lung injury model , better homing capacity to bone marrow in irradiated mice (Chen et al., 2013) , and mobilization and enhanced neuroprotection in a rat cerebral ischemia model (Yu et al., 2012) . However, genetic modification of NSCs to enhance their migration toward brain malignancy has never previously been explored.
Non-immunogenic glioma-tropic NSCs have been known to be an effective carrier of OVs (Ahmed et al., 2011a) in the mouse model of glioma. A study by Zhao et al. (2008) showed that hypoxia is a key factor in determining NSC tropism to glioma and that multiple signaling pathways mediate this phenomenon. Several other studies delineate a critical role of hypoxia in promoting survival and increasing the motility and regenerative capacity of stem cells (Rosova et al., 2008; Wang et al., 2013) . In line with the current literature, our results also show that hypoxic preconditioning of NSCs results in an increased migratory phenotype of the NSCs, in part due to enhanced expression of CXCR4 on the cell surface, and allows for efficient intracellular viral replication. However, hypoxic preconditioning is known to initiate other changes in signaling, leading to upregulation of numerous chemokine receptors and proteins involved in migration of NSCs (Zhao et al., 2008) . In our study, hypoxia preconditioning affected mRNA expression of several stemness and differentiation markers in NSCs. To overcome this limitation, we generated genetically modified NSCs overexpressing CXCR4, thus providing certainty to the fate of therapeutic stem cells. Genetic modification of NSCs had no effect on the NSC phenotype at either RNA or protein level and allowed for effective viral replication. Moreover, CXCR4-overexpressing NSCs demonstrated genetic stability as assessed by cytogenetic analysis. CXCR4/SDF-1 interaction is necessary for the migration of neural progenitors in the developing brain (Li and Ransohoff, 2008) . The binding of SDF-1 to CXCR4 can lead to the activation of multiple signaling pathways in the CNS, such as phosphatidylinositol 3-kinase-AKT, mitogen-activated protein kinase, and nuclear factor kB (Li and Ransohoff, 2008) . Migration is a complex process involving cooperative signaling events. SDF-1/ CXCR4 has been shown to play a critical role in NSC migration through activation of p38 MAPK, PAXILLIN, and cJUN (Imitola et al., 2004) . These reports corroborate our data demonstrating that overexpression of CXCR4 endows increased migration ability to the HB1F3.CD cells.
MGs are known to secrete SDF-1, and radiation therapy further increases SDF-1 levels (Bajetto et al., 2006; Balyasnikova et al., 2014; Wang et al., 2013) . Thus, the CXCR4/ SDF-1 axis may be essential for increased NSC motility toward GBM. Indeed, after radiation animals treated with either H NSCs-OVs or CXCR4 NSC-OVs demonstrated higher presence of viral protein in the tumor vicinity and survived significantly longer than animals treated with N NSCs-OVs or VC NSCs-OVs. As radiation therapy is an integral part of the current treatment regimen for MG, the strategy of enhancing the chemotactic properties of NSCs via modulation of CXCR4 expression should be further explored in Figure 5 .
Irradiation Increases SDF-1 Expression in GBM43 Xenograft
The analysis of H&E staining and immunocytochemistry of brain tissue sections from control and irradiated mice demonstrates reduced tumor burden but increased SDF-1 levels at the tumor sites after XRT treatment.
(A) SDF-1 expression (green) is strongly localized at the tumor site (white boxes) after irradiation (2 Gy 3 5 days).
(B) Densitometry quantification of the viewing fields demonstrates a 4-fold increase in SDF-1 expression in XRT-treated animals in comparison with control animals (n = 3 experiments; ***p < 0.001, Student's t test, error bars with SEM).
various therapeutic settings. We envision that an ideal clinical timing for intranasal oncolytic therapy via CXCR4 NSCs would be following standard radiotherapy. The non-invasive nature of intranasal delivery would allow for repeated treatments. CXCR4 NSCs can be prepared in large quantities for clinical use, circumventing the logistically challenging hypoxia pretreatment. Given the high translational value of this approach, we urge caution regarding the limitations of preclinical rodent models. It is well known that normal and cancerous mouse tissues are poorly permissive for OVs, and CRAds are rapidly cleared in immunocompetent hosts, rendering the immunocompetent mouse unsuitable for CRAd studies. Although both cotton rat and Syrian hamster are CRAd-permissive animal models with intact immune systems, no glioma models are currently available for studies in these animals (Ahmed et al., 2010) . Our previous studies in the cotton rat model have demonstrated the improved dissemination and persistence of OV by autologous stem cells, which efficiently shielded virus and suppressed antiCRAd immune response, allowing us to project efficient entry and propagation of CRAds in glioma cells in immunocompetent hosts (Ahmed et al., 2010) . Furthermore, NSCs can successfully disseminate OV in the tumor environment , which results in superior therapeutic outcome in comparison with CRAd virotherapy alone (Ahmed et al., 2013) . Lastly, the immune response against OV in immunocompetent hosts (Jiang et al., 2014) may assist in the bystander anti-glioma activity of the proposed therapy.
Finally, we recognize that rodent models for intranasal delivery of NSCs have intrinsic limitations, such as the relative size and anatomical differences in the nasal and olfactory systems between humans and mice. Despite differences in the anatomy of the nasal cavity, larynx, and pharyngeal details (Harkema et al., 2006) , the fundamental structures and layouts of the olfactory systems are well preserved across vertebrate species (Ache, 2010) , offering a compelling basis for extrapolating basic cellular and molecular phenomena from rodent models to human scenarios. Unlike rodents, humans do not rely on olfactory sensation for survival and have smaller olfactory systems (3% of the nasal epithelium is olfactory) (Harkema et al., 2006) compared with rodents (50%) (Gross et al., 1982) , which may imply that intranasal delivery would be a less effective route of NSC entry in humans. However, the rodent olfactory nasal epithelium surface area ranges between 125.5 ± 4.0 and 136.9 ± 7.3 mm 2 in adult mice (Gross et al., 1982) , whereas humans have about 500 mm 2 on average (Harkema et al., 2006) , which might offer more entry access for NSCs. In addition, trigeminal nerves offer additional entry routes for NSCs into the brain (Dhuria et al., 2010) . Furthermore, we will be able to achieve more precise delivery of NSCs to the cribriform plate using catheter-based delivery. However, to truly understand the effectiveness of stem cell penetration to the brain from the nasal cavity, studies in large animal models such as monkey should be conducted. Our study demonstrates that for intranasal delivery of NSCs-OV to be efficacious, hypoxia preconditioning or genetically engineering NSCs to overexpress CXCR4 is required to further enhance the penetration of NSCs into the brain. This corroborates our previous observation that direct intratumoral delivery of NSCs loaded with OVs generates a more potent response than a distant site of delivery (Ahmed et al., 2013) due to the lower number of NCSs reaching the tumor from a distant site. Although both intracavitary and intrathecal delivery of NSCs in the context of brain tumor are clinically relevant, they are invasive and do not lend themselves to multiple dosing. The restrictions of systemic delivery of therapeutic agents for brain tumor Figure 6 . Hypoxia Pretreatment and CXCR4 Overexpression in NSCs Are Necessary for Effective Intranasal Delivery of OVLoaded NSCs in Irradiated Animals (A) When given only PBS intranasally, radiation therapy significantly enhanced survival of mice bearing aggressive patientderived GBM43 glioma xenografts (median survival increased by 9 days; n = 8 animals/group; ***p < 0.001, log-rank test). (B) However, there was no further improvement in survival when mice were treated with intranasal OV, N NSCs, or N NSCs + OV following XRT treatment. Treatment of mice with OV-loaded H NSCs resulted in significant improvement in the survival of mice (5 days; n = 8; *p < 0.05, log-rank test) after irradiation. (C) Significant improvement in survival of mice after XRT was also achieved with OV-loaded genetically enhanced CXCR4 NSCs (9 days of median survival benefits; n = 8; **p = 0.0013, log-rank test).
have been well documented in the literature, with a major limitation being the phenomenon of first-pass clearance (Lesniak and Brem, 2004) . For similar reasons, we did not consider the systemic route of delivery as viable for NSCbased OV therapy due to the fast elimination of NSCs from systemic circulation (Aboody et al., 2006) , high uptake of CRAd by liver tissue (Waddington et al., 2008) , and potential hepatotoxicity. Intranasal delivery is an attractive alternative due to its non-invasive and repeatable nature and its potential for targeting inoperable brain malignancies, such as multiple brain metastases or invasive tumors. We hypothesize that CXCR4 enhancement would be beneficial to all applicable routes of delivery, given that the SDF-1 chemotaxis gradient derived from tumor growth and heightened by radiotherapy may be established across the CNS. Therefore, the development of strategies enhancing the number of therapeutic NSCs arriving at the brain tumor using the intranasal route should be further pursued.
In summary, the current report builds on our previous validation of the intranasal delivery of stem cells as a feasible route for anti-glioma therapy. Here we show that NSCs can be repeatedly delivered intranasally to extend the survival benefits of oncolytic virotherapy against glioma in animal models. We identified that hypoxia pretreatment of NSCs enhances the migratory potential of NSCs via the SDF-1/CXCR4 signaling axis. Furthermore, NSCs genetically modified to overexpress CXCR4 provide efficient delivery of the OV payload to glioma, resulting in significant survival benefits in conjunction with radiotherapy. The strategy of intranasal delivery of various therapeutics by potent stem cell carriers should be further evaluated in the context of brain malignancies for future transition to the clinic.
EXPERIMENTAL PROCEDURES
See also Supplemental Experimental Procedures.
Cell Culture and Reagents
U87MG cells and human NSCs (HB1.F3.CD) were maintained in DMEM (Corning) with 10% fetal bovine serum (FBS; Hyclone). Patient-derived GBM43 and GBM6 glioma cells were routinely maintained as mouse flank tumors, and were subsequently isolated and maintained in 10% FBS (Hyclone) DMEM (Sarkaria et al., 2006) or in serum-free neurobasal medium supplemented with B27, N2, basic fibroblast growth factor (20 ng/mL), and epidermal growth factor (20 ng/mL; all reagents from Life Technologies). CXCR4-overexpressing NSCs ( CXCR4 NSCs) were generated by transduction of HB1.F3.CD cells with lentivirus encoding for CXCR4 cDNA (GenTarget), along with vector-only control NSCs ( VC NSCs) from the same passage of NSCs.
Hypoxic Culture
NSCs were cultured in a humidified hypoxic gas flow chamber at 37 C (Coy Laboratory Products) with sustained 1% O 2 and 5% CO 2 for 24 hr ( H NSCs). Control NSCs were maintained under the same culture condition but at atmospheric O 2 levels ( N NSCs).
Loading of NSCs with Oncolytic Virus
The generation of replication competent adenoviral vector CRAd-S-pk7, which contains the wild-type adenovirus replication protein E1A under the control of human survivin promoter, has been previously described (Ulasov et al., 2007 NSCs were infected with 50 CRAd-S-pk7 particles/cell. After 1 hr of incubation, cells were washed three times to remove unbound viral particles and grown in fresh complete growth medium. After 72 hr, cells and medium were collected and freezethawed three times to release infectious progeny. Lysates were N NSCs (n = 10 sections from 3 animals/group; ***p < 0.001, Student's t test). (B) Using GBM43 cells expressing blue fluorescent protein, we also demonstrate much improved OV delivery to the tumor site using CXCR4 NSCs when compared with VC NSCs (n = 10 sections from 3 animals/group; ***p < 0.001, Student's t test, error bars with SEM).
cleared by centrifugation and titrated over adherent HEK293 cells with 10-fold dilution. After 48 hr, cells were fixed and stained for viral hexon protein detection using an Adeno-X Rapid Titer Kit (Clontech). The titration (i.e., infectious) units were calculated to determine the viral progeny release.
Patient-Derived Xenograft Mouse Model of GBM
All protocols were approved by the Institutional Committee on Animal Use at The University of Chicago. The surgical procedures were conducted according to the NIH guidelines on the care and use of laboratory animals. Six-to eight-week-old athymic nude male mice were obtained from Harlan Laboratories and maintained in a pathogen-free facility. Mice were anesthetized with ketamine-HCl (25 mg/mL)/xylazine (2.5 mg/mL) solution, and GBM43 or GBM6 cells were injected in the mouse brain at 2 3 10 4 or 1 3 10 5 cells in 2.5 mL of sterile saline, respectively, using the established procedure (Ahmed et al., 2013) . Standard postsurgery care was given following a protocol approved by the Institutional Animal Care and Use Committee.
Radiation Therapy and Intranasal Stem Cell Therapy
Select groups of glioma xenograft mouse models underwent XRT as detailed in the Results section. Specifically, after ketamine and xylazine anesthesia, the entire body of animals excluding the head was shielded with lead and was exposed to a 2-Gy daily dose of radiation for five consecutive days starting on the eighth day after tumor cell xenograft (days 8-12). Seven days following the first XRT treatment and weekly thereafter (days 14, 21, and 28), animals were treated either with sterile saline or NSCs loaded with OV (see below). In brief, after anesthesia the mice were inoculated with 5 3 10 5 NSCs in 12 mL of sterile saline (given as three fractions at 5-min intervals) via the nasal cavity as previously described with small modifications . All mice were followed to assess their survival. Upon appearance of signs of morbidity, mice were euthanized and whole brain tissues were excised immediately or after intracardiac perfusion with PBS or 4% paraformaldehyde, and embedded in OCT compound (Sakura Finetek). Sections (10-20 mm) were cut, air dried, and stained with H&E or processed for SDF-1 or hexon fluorescence staining as detailed under Immunocytochemistry in Supplemental Experimental Procedures.
Statistical Analysis
All statistical analyses were performed with Student's t test using GraphPad Prism 4 (GraphPad Software) unless specified otherwise. The sample size for each group was R3, where n represents biological replicates unless otherwise indicated. All numerical data are reported as means ± SEM. A Kaplan-Meier survival curve was generated and a log-rank test was applied to compare survival distributions. For all survival experiments, n represents the number of animals per group. All reported p values were two-sided and were considered to be statistically significant at *p < 0.05, **p < 0.01, and ***p < 0.001. 
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